Risk factors for doxorubicin-induced congestive heart failure - PubMed

Risk factors for doxorubicin-induced congestive heart failure

D D Von Hoff et al. Ann Intern Med. 1979 Nov.

Abstract

Potential risk factors responsible for development of doxorubicin-induced congestive heart failure were examined through retrospective analysis of 4018 patient records. The overall incidence of drug-induced congestive heart failure was 2.2% (88 cases). The probability of incurring doxorubicin-induced congestive heart failure was related to the total dose of doxorubicin administered. There was a continuum of increasing risk as the cumulative amount of administered drug increased. A weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule. An increase in drug-related congestive heart failure was also seen with advancing patient age. Performance status, sex, race, and tumor type were not risk factors. These data will enable clinicians to better estimate the risk/benefit ratio in individual patients receiving prolonged administration of doxorubicin. They also provide a basis for the investigation of less cardiotoxic anthracycline analogues or for designing measures to prevent doxorubicin-induced cardiomyopathy.

Similar articles

• Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules.

  Berrak SG, Ewer MS, Jaffe N, Pearson P, Ried H, Zietz HA, Benjamin RS. Berrak SG, et al. Oncol Rep. 2001 May-Jun;8(3):611-4. doi: 10.3892/or.8.3.611. Oncol Rep. 2001. PMID: 11295089

• Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.

  Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D'Angio GJ, Breslow NE. Green DM, et al. J Clin Oncol. 2001 Apr 1;19(7):1926-34. doi: 10.1200/JCO.2001.19.7.1926. J Clin Oncol. 2001. PMID: 11283124

• Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.

  Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Fraschini G, Frye DK, Buzdar AU. Ibrahim NK, et al. Cancer Chemother Pharmacol. 1999;43(6):471-8. doi: 10.1007/s002800050926. Cancer Chemother Pharmacol. 1999. PMID: 10321507

• Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity.

  Steinberg JS, Wasserman AG. Steinberg JS, et al. Clin Ther. 1985;7(6):660-7. Clin Ther. 1985. PMID: 3907840 Review.

• Adriamycin (doxorubicin) cardiotoxicity: a review.

  Chlebowski RT. Chlebowski RT. West J Med. 1979 Nov;131(5):364-8. West J Med. 1979. PMID: 394479 Free PMC article. Review.

Cited by

• MicroRNA‑133b alleviates doxorubicin‑induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2.

  Li Z, Ye Z, Ma J, Gu Q, Teng J, Gong X. Li Z, et al. Int J Mol Med. 2021 Jul;48(1):125. doi: 10.3892/ijmm.2021.4958. Epub 2021 May 13. Int J Mol Med. 2021. PMID: 33982775 Free PMC article.

• Mechanism-based engineering against anthracycline cardiotoxicity.

  Force T, Wang Y. Force T, et al. Circulation. 2013 Jul 9;128(2):98-100. doi: 10.1161/CIRCULATIONAHA.113.003688. Epub 2013 Jun 11. Circulation. 2013. PMID: 23757311 Free PMC article. No abstract available.

• Noninvasive diagnosis of chemotherapy related cardiotoxicity.

  Gillespie HS, McGann CJ, Wilson BD. Gillespie HS, et al. Curr Cardiol Rev. 2011 Nov;7(4):234-44. doi: 10.2174/157340311799960672. Curr Cardiol Rev. 2011. PMID: 22758624 Free PMC article. Review.

• Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.

  Khouri MG, Klein MR, Velazquez EJ, Jones LW. Khouri MG, et al. Future Cardiol. 2015 Jul;11(4):471-84. doi: 10.2217/fca.15.16. Epub 2015 Aug 3. Future Cardiol. 2015. PMID: 26235924 Free PMC article. Review.

• Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice.

  Dolinsky VW, Rogan KJ, Sung MM, Zordoky BN, Haykowsky MJ, Young ME, Jones LW, Dyck JR. Dolinsky VW, et al. Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E243-53. doi: 10.1152/ajpendo.00044.2013. Epub 2013 May 21. Am J Physiol Endocrinol Metab. 2013. PMID: 23695218 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database